1-2 of 2
Robert Raju
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Clinical Trials & Observations
Nicholas Di Bella, Raymond Taetle, Kathryn Kolibaba, Thomas Boyd, Robert Raju, David Barrera, Ernest W. Cochran, Jr, Philip Y. Dien, Roger Lyons, Peter J. Schlegel, Svetislava J. Vukelja, Julie Boston, Kristi A. Boehm, Yunfei Wang, Lina Asmar
Journal: Blood
Blood (2010) 115 (3): 475–480.
https://doi.org/10.1182/blood-2009-08-233155
Published: 2010
Journal Articles

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Ayad Al-Katib, MD, David D. Hurd, MD, Robert Raju, MD, Joe Stephenson, MD, Francis Giles, MD, Eric Haltom, Margaret J. Uprichard, PharmD
Journal: Blood
Blood (2004) 104 (11): 1403.
https://doi.org/10.1182/blood.V104.11.1403.1403
Published: 2004